Crossmark

: KS: Honoraria: Otsuka, Amgen, Chugai Pharma. Consulting or Advisory Role: Novartis, Pfizer, Takeda. Research Funding: Novartis, Enliven Therapeutics. Travel, Accommodations, Expenses: Otsuka, Amgen. GMB: Research Funding: IFM Therapeutics, Takeda. TK: Honoraria: CURE. Consulting or Advisory Role: Novartis, Jazz Pharmaceuticals, Pfizer, AbbVie/Genentech, Agios, Daiichi Sankyo/UCB Japan, Liberum, Sanofi, Servier, Pinot Bio, Sellas Life Sciences, Bristol Myers Squibb/Celgene. Research Funding: Bristol Myers Squibb, Celgene, Amgen, BiolineRx, Incyte, Genentech/AbbVie, Pfizer, Jazz Pharmaceuticals, AstraZeneca, Astellas Pharma, Ascentage Pharma, Genfleet Therapeutics, Cyclacel, Pulmotech, cellenkos, Glycomimetics, Astex Pharmaceuticals, Iterion Therapeutics, Delta-Fly Pharma, Regeneron, Sellas Life Sciences, Abcuro, DAAN Biotherapeutics. GB: Consulting or Advisory Role: Argenx, PTC Therapeutics, BiolineRx, BioTheryX, Nkarta, Treadwell Therapeutics, Novartis, Catamaran Bio, Takeda, AbbVie. Research Funding: Incyte, GlaxoSmithKline, Cyclacel, BiolineRx, MedImmune, Lilly, Oncoceutics, Ryvu Therapeutics, Janssen Scientific Affairs, Bristol Myers Squibb, AbbVie, Novartis, AstraZeneca, Mundipharma Research, PTC Therapeutics, BioTheryX, XBiotech, Arvinas, Astex Pharmaceuticals, TCR2 Therapeutics, Nkarta, Nkarta, Treadwell Therapeutics, Cellestia Biotech. CD: Honoraria: AbbVie, GlaxoSmithKline, Servier, Genentech/AbbVie, Astellas Pharma, Bristol Myers Squibb Foundation, Schrodinger, Daiichi Sankyo/Astra Zeneca, Ellipses Pharma. Consulting or Advisory Role: AbbVie, AstraZeneca, Genmab, Molecular Partners, Servier, Schrodinger, Rigel, Ryvu Therapeutics. Research Funding: AbbVie, Cleave Therapeutics, Foghorn Therapeutics, Immune-Onc Therapeutics, Jazz Pharmaceuticals, Servier, Loxo/Lilly, Astex Pharmaceuticals, Bristol Myers Squibb/Celgene, BeiGene, Remix Therapeutics. NS: Honoraria: Amgen. Consulting or Advisory Role: AstraZeneca, NGM Biopharmaceuticals, Pfizer, Takeda, Novartis, Amgen. Research Funding: Takeda, Astellas Pharma, Stemline Therapeutics. NP: Consulting or Advisory Role: Blueprint Medicines, Pacylex, Immunogen, Bristol Myers Squibb, Clearview Healthcare Partners, Astellas Pharma, CTI BioPharma Corp, AbbVie, Aptitude Health, Aplastic Anemia and MDS International Foundation, CancerNet, CareDx, Celgene, Cimeio Therapeutics, Curio Science, Dava Oncology, EUSA Pharma, Harborside Press, Imedex, Intellisphere, Intellisphere, Magdalen Medical Publishing, Medscape, Menarini Group, Neopharm, Novartis, OncLive, Patient Power, Peerview, Pharmaessentia, Physicans’ Education Resource. Research Funding: US DOD. EJ: Consulting or Advisory Role: Pfizer, Takeda, Amgen, AbbVie, Bristol Myers Squibb, Adaptive Biotechnologies, Genentech, Autolus, Ascentage Pharma, Taiho Pharmaceutical, Novartis, TargetRX, Terns Pharmaceuticals. Research Funding: Pfizer, Adaptive Biotechnologies, Ascentage Pharma Group, AbbVie, Takeda, Johnson & Johnson/Janssen, Jazz Pharmaceuticals, Terns Pharmaceuticals, Taiho Pharmaceutical, Novartis, Amgen, TGRX. Travel, Accommodations, Expenses: Pfizer, Aptitude Health, Autolus, Nucleus Global, ONVIV, MD Education, HMP Education, Daiichi Sankyo Nordics. ND: Consulting or Advisory Role: Celgene, Agios, Jazz Pharmaceuticals, Pfizer, AbbVie, Astellas Pharma, Daiichi Sankyo, Novartis, Bristol Myers Squibb, Amgen, Immunogen, Genentech, Servier, Syndax, Trillium Therapeutics, Gilead Sciences, Arog, Shattuck Labs, Kite, a Gilead company, Stemline/Menarini. Research Funding: Bristol Myers Squibb, Pfizer, Immunogen, Genentech, AbbVie, Astellas Pharma, Servier, Daiichi Sankyo, Gilead Sciences, Amgen, Trillium Therapeutics, Hanmi, Trovagene, FATE Therapeutics, Novimmune, Glycomimetics, Kite, a Gilead company. FR: Honoraria: Amgen, Pfizer, Astellas Pharma, Celgene, Agios, AbbVie/Genentech, AstraZeneca, Bristol Myers Squibb, Takeda, Jazz Pharmaceuticals, Novartis, Syros Pharmaceuticals, Taiho Pharmaceutical, Syndax. Consulting or Advisory Role: Amgen, Astellas Pharma, Celgene, Jazz Pharmaceuticals, Agios, AbbVie/Genentech, Bristol Myers Squibb, AstraZeneca, Taiho Oncology, Syros Pharmaceuticals, Certara Inc. Research Funding: Bristol Myers Squibb, Amgen, Macrogenics, Xencor, Selvita, Cellerant, Astex Pharmaceuticals, Taiho Oncology, Syros Pharmaceuticals, Prelude Therapeutics, Biomea Fusion, Astellas Pharma. HK: Honoraria: AbbVie, Amgen, Pfizer, Ascentage Pharma Group, Ipsen, KAHR Medical, Novartis, Shenzhen Target Rx, Daiichih-Sankyo, Immunogen. Consulting or Advisory Role: AbbVie. Research Funding: Amgen, Bristol Myers Squibb, Novartis, AbbVie, Immunogen, Jazz Pharmaceuticals, Ascentage Pharma, Daiichi Sankyo/Lilly. GGM: Honoraria: Curis, Bristol Myers Squibb/Celgene, Taiho Oncology, Ascentage Pharma, Servier, Keros Therapeutics. Consulting or Advisory Role: Bristol Myers Squibb, Taiho Oncology, Curis, Ascentage Pharma, Servier, Keros Therapeutics. Research Funding: Novartis, AbbVie, Bristol Myers Squibb, Genentech, Curis, Rigel, Taiho Oncology, Stemline Therapeutics, Zentalis, Chordia Therapeutics, Jazz Pharmaceuticals. The remaining authors declare no competing interests.

: All methods were performed in accordance with the relevant guidelines and regulations. This study was approved by the MD Anderson Institutional Review Board (protocol # 2024-0341). The need for informed consent was waived due to the retrospective, non-interventional nature of this study.

Document is current

Any future updates will be listed below